Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A HDL-based cirrhosis risk score improves the prediction of short-term mortality in acutely decompensated cirrhosis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Prognostic Value of Exercise Testing in Patients with Liver Cirrhosis.

Diagnostics (Basel, Switzerland)·2026
Same author

Noninvasive mean pulmonary arterial pressure/oxygen uptake slope as a predictor of pulmonary exercise haemodynamics and outcome.

ERJ open research·2026
Same author

The Clinical Relevance of Unclassified Pulmonary Hypertension.

Chest·2026
Same author

Brepocitinib, a selective TYK2/JAK1 inhibitor, mitigates neutrophilic inflammation and glucocorticoid receptor-β expression in COPD.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study.

Clinical nutrition (Edinburgh, Scotland)·2025
Same journal

Pulmonary Vascular Disease Across the Continuum: From Mechanisms to Precision Care.

Heart failure clinics·2026
Same journal

Long-term Complications of Pulmonary Embolism: Which Is the Optimal Follow-Up?

Heart failure clinics·2026
Same journal

Recent Advances in Pulmonary Hypertension Management.

Heart failure clinics·2026
Same journal

The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary Hypertension.

Heart failure clinics·2026
Same journal

Exercise Training and Cardiac Rehabilitation in Chronic Thromboembolic Pulmonary Hypertension.

Heart failure clinics·2026
Same journal

Long-term Complications of Venous Thromboembolism: A Practical Guide.

Heart failure clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Portopulmonary Hypertension: Current Perspectives.

Teresa John1, Rudolf E Stauber2, Philipp Douschan1

  • 1Division of Respiratory Medicine, Lung Research Cluster, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.

Heart Failure Clinics
|June 17, 2026
PubMed
Summary
This summary is machine-generated.

Portopulmonary hypertension (PoPH) is a serious complication in liver disease patients, impacting heart function and survival. This review covers PoPH

Keywords:
Chronic liver diseaseLiver cirrhosisPortopulmonary hypertensionPulmonary hypertension

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Area of Science:

  • Cardiology
  • Hepatology
  • Pulmonology

Background:

  • Portopulmonary hypertension (PoPH) is pulmonary arterial hypertension associated with portal hypertension.
  • It affects approximately 5% of patients with cirrhosis.
  • PoPH increases right cardiac afterload, leading to right heart failure and complicating liver disease management.

Purpose of the Study:

  • To review current literature on Portopulmonary hypertension pathophysiology.
  • To focus on cardiopulmonary hemodynamics, clinical presentation, diagnostic challenges, and management strategies for PoPH.

Main Methods:

  • Comprehensive literature review of Portopulmonary hypertension.
  • Analysis of studies focusing on hemodynamics, clinical aspects, diagnosis, and treatment.

Main Results:

  • PoPH significantly increases morbidity and mortality in chronic liver disease.
  • Understanding PoPH pathophysiology is crucial for effective management.
  • Diagnostic challenges and evolving management strategies are highlighted.

Conclusions:

  • Portopulmonary hypertension is a critical complication of portal hypertension.
  • Further research into PoPH hemodynamics and management is warranted.
  • Integrated care is essential for patients with PoPH and liver disease.